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Abstract
Objective: GTP cyclohydrolase I (GCH1) is the rate-limiting enzyme for tetrahydrobiopterin biosynthesis and has been
shown to be a promising therapeutic target in ischemic heart disease, hypertension, atherosclerosis and diabetes. The
endogenous GCH1-interacting partners have not been identified. Here, we determined endogenous GCH1-interacting
proteins in rat.
Methods and Results: A pulldown and proteomics approach were used to identify GCH1 interacting proteins in rat liver,
brain, heart and kidney. We demonstrated that GCH1 interacts with at least 17 proteins including GTP cyclohydrolase I
feedback regulatory protein (GFRP) in rat liver by affinity purification followed by proteomics and validated six protein
partners in liver, brain, heart and kidney by immunoblotting. GCH1 interacts with GFRP and very long-chain specific acyl-
CoA dehydrogenase in the liver, tubulin beta-2A chain in the liver and brain, DnaJ homolog subfamily A member 1 and fatty
aldehyde dehydrogenase in the liver, heart and kidney and eukaryotic translation initiation factor 3 subunit I (EIF3I) in all
organs tested. Furthermore, GCH1 associates with mitochondrial proteins and GCH1 itself locates in mitochondria.
Conclusion: GCH1 interacts with proteins in an organ dependant manner and EIF3I might be a general regulator of GCH1.
Our finding indicates GCH1 might have broader functions beyond tetrahydrobiopterin biosynthesis.
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Introduction
Tetrahydrobiopterin (BH4) is an essential cofactor for phenyl-
alanine hydroxylase, tyrosine hydroxylase, tryptophan hydroxy-
lase, and nitric oxide synthases (NOS) and alkylglycerol monoox-
ygenase [1]. The normal BH4 level is required for the degradation
of phenylalanine, the biosynthesis of catecholamine, serotonin,
and the balance of nitric oxide and superoxide [2]. GTP
cyclohydrolase I (GCH1) is the first and rate-limiting enzyme in
the de novo pathway of BH4 biosynthesis [3]. Mutation of GCH1
resulted in greatly reduced BH4 levels which has been shown to
cause neurological diseases such as dopamine-responsive dystonia
(DRD) [4] and atypical severe phenylketonuria (PKU) [5]. Single
nucleotide polymorphisms in GCH1 were associated with
increased susceptibility of patients to develop neuropathic and
inflammatory pain [6,7]. Recently GCH1 has been linked to
hypertension, atherosclerosis, diabetes, cardiac hypertrophy, and
myocardial ischemia [2] and has become a potential therapeutic
target in cardiovascular disease. Previously we have found that
GCH1 confers the increased resistance to myocardial ischemia in
Brown Norway rats compared to Dahl S rats [8]. Over-expression
of GCH1 restores ischemic preconditioning during hyperglycemia
[9], protects against acute cardiac allograft rejection [10],
attenuates blood pressure progression in salt-sensitive low-renin
hypertension [11], and reduces endothelial dysfunction and
atherosclerosis in ApoE-knockout mice [12]. However, the
understanding of molecular mechanisms of the protective
functions by GCH1 remains very limited.
GCH1 is regulated by protein-protein interaction. GFRP
specifically binds to GCH1 and mediates BH4 feedback inhibition
and phenylalanine feed-forward stimulation of GCH1 activity
[13,14]. It was reported that the N-terminal peptide of GCH1 is
the auto-inhibitory control element that contributes to bind to
GFRP [15]. In endothelial cells, the phosphorylation status of
GCH1 seems to impact the interaction between GCH1 and GFRP
and modulate BH4 production [16]. However, the mRNAs of
GFRP and GCH1 are not always co-expressed. For examples,
GFRP expression is lacking in some rat tissues such as pineal and
adrenal glands [3], and some species like drosophila [17].
Furthermore, in endothelial cell lines, over-expression or knock-
down of GFRP did not affect GCH1 activity or BH4 production
[18]. Therefore, it is important to discover other potential protein
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and others have identified some GCH1-interacting partners in
exogenous GCH1 over-expressing cell lines [19], yeast [20] and
drosophila [21], however, the identities of endogenous GCH1-
interacting partners in different organs remain unknown.
Accordingly, in this study we aimed at identifying the
endogenous GCH1-interacting proteins in rat and characterize
the interaction between GCH1 and its protein partners in different
rat organs as well as the sub-cellular distribution of GCH1. We
demonstrated here that GCH1 interacts with 17 proteins including
GFRP in rat liver and the protein interaction profiles were quite
different in brain, heart, liver and kidney except a common
partner newly identified by this study, eukaryotic translation
initiation factor 3 subunit I (EIF3I). In addition, GCH1 interacts
with mitochondria proteins and has functional distribution in
mitochondria.
Materials and Methods
Ethics Statement
All animal protocols were approved by the Institutional Animal
Care and Use Committee of the Medical College of Wisconsin.
Rats used in this study received humane care in compliance with
the Guide for the Care and Use of Laboratory Animals by the
National Research Council.
Materials
Polyclonal GCH1 antibody was generously provided by Dr.
Zvonimir S. Katusic [22]. Antibody against GFRP was from
Abnova, antibody against tubulin beta-2A chain (TBB2A) was
from Sigma. Antibodies against EIF3I, VLCAD, ALDH, and
DNJA1 were from Santa Cruz Biotechnology.
Whole Animal Vascular Perfusion
Sprague Dawley male rats (10–12 weeks) were obtained from
Charles River (Wilmington, Mass).
Rats were maintained on a regular chow with unlimited access
to water. Once anesthetized, the rat thoracic cavity was promptly
opened and clamped to expose heart and provide drainage for
blood and fluids. Then, a needle connected with a perfusion bottle
containing PBS was inserted into left ventricle and a small cut was
made in atrium. The perfusion pressure was maintained at
,80 mmHg. The rat was perfused with PBS until the blood was
completely cleared from the organs (,15 min). The brain, heart,
liver and kidney were rapidly excised, frozen in liquid nitrogen and
stored at 280uC until use.
Plasmid and Cell Culture
Rat GCH1 and GFRP were cloned into pcDNA5.0 vector with
Flag or HA tag in the N-terminal. The plasmids were transfected
into human embryonic kidney cell line (HEK) Flp-in cells
(Invitrogen) by Lipofectamine 2000 (Invitrogen, Carlsbad, CA).
The Flag-GCH1 stable cell line was established as previously
described [23].
Antibody Conjugation
The GCH1 antibody and normal rabbit IgG were covalently
conjugated to protein A/G plus agarose by disuccinimidyl
suberate (DSS) using Pierce Crosslink Immunoprecipitation Kit
(Rockford, IL). The resin (20 ml) was washed with 200 mlo f
coupling buffer (0.01 M sodium phosphate, 0.15 M NaCl; pH 7.2)
twice. The resin was then incubated with 10 mg antibody in 100 ml
coupling buffer for 60 min. The antibody bound resin was washed
three times with coupling buffer and crosslinked by incubating in
450 mM of DSS for 60 min at room temperature. Later elution
buffer (provided with the kit, pH 2.8, containing primary amine)
was added three times to remove the non-crosslinked antibody and
the flow-through (the Eluates 1–3) was saved and used to verify the
crosslinking. Part of the crosslinked antibody was incubated with
GCH1-HEK cell lysates or rat liver homogenates overnight and
eluted with the elution buffer. The flow-through of these samples,
the first elution collected (Elution 1) as well as the Eluates 1 and 3
were Coomassie stained or processed for western blot analysis for
GCH1 to check the efficiency of the crosslinking. A total of 300 mg
GCH1 antibody was conjugated to the resin and stored in
coupling buffer at 4uC.
GCH1 Protein Complexes Purification
The perfused liver, brain, heart and kidney were homogenized
in MOPS lysis buffer [23] and a total of ,150 mg protein lysates
were used in the purification. The protein lysates were pre-cleared
by incubation with a mixture of protein A/G plus agarose (4 ml)
and normal rabbit IgG (2 mg) for 2 hr. The supernatant was split
into two to incubate either with GCH1 antibody-conjugated
agarose or IgG-conjugated agarose in column with end-over-end
rotation overnight at 4uC. The flow-through was saved for
verification. The protein and agarose mixture were washed with
2506 column volume of washing buffer (150 mM NaCl and
50 mM Tris-HCL, PH, 7.5). The IgG and GCH1 protein
complexes were eluted by adding 1 ml elution buffer and
incubated for 3 min. The column was eluted for 6 times and the
eluate was quickly neutralized with 1 M Tris (PH 9.5). The
column was then washed with 206 column volume of washing
buffer twice for neutralization followed by elution with 206
column volume of elution buffer twice to clean the antibody-
conjugated agarose. The column was then stored in storage buffer
(50% glycerol and 0.02% sodium azide in washing buffer) at 4uC
for repeat use.
Liquid Chromatography Mass Spectrometry (LC/MS)
Analysis
100 ml of the first and the second elution, respectively, were
combined and precipitated with acetone. The protein pellet was
dissolved in 15 ml of 400 mM ammonium bicarbonate. Five mlo f
the proteins solution were reduced with 5 ml of 40 mM DTT for
3h ra t3 7 uC followed by alkylation with 5 ml of 30 mM iodoacetic
acid for 30 min at 37uC. The proteins were then digested by 1 mg
trypsin (Promega, Madison, WI) and diluted in 15 ml of 400 mM
ammonium bicarbonate overnight at 37uC. The digestion was
quenched by adding 3 mL acetic acid. The resulting peptide
mixture (4 ml) was separated by two-dimensional nano LC system
(Eksigent technologies, Dublin, CA) using a Zorbax SB300-C8
trap (Agilent technologies, Santa Clara, CA) followed by reverse
phase gradient onto a 0.1 mm6100 mm column (5 mm, 300 A ˚)
packed in-house with magic C18 material (Michrom Bioresources,
Auburn, CA). The separated peptide mixture was analyzed on-line
with a LTQ mass spectrometer (Thermo Scientific, Bremen,
Germany). In these LC/MS experiments, a full MS scan was
acquired in parallel with data dependent MS/MS scans of the top
five most abundant m/z peaks. MS/MS was performed with
wideband activation, dynamic exclusion of 1 for 60 seconds with a
list of 300 m/z and a width of
+/2 1.5/0.5 m/z, collision energy
of 35%, and noise level of 3000 NL. The peaklist-generating
software is Xcalibur (2.0.5) (Thermo Scientific). The LC/MS/MS
data were searched with Bioworks 3.0 (Thermo Scientific) against
a rat database from Swissprot (7491 proteins reviewed, the
database was current in October 2010) with its reversed sequences.
Search parameters included trypsin digestion (K, R C-terminal
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site (non-specific cleavages were not permitted), amino acid length
of 6 to 100 with tolerance of 1.4 Da, dynamic modifications of
methionine methylation (+14 Da) and cysteine carboxyamido-
methylation (+57 Da). Mass tolerance for fragment ions is 1 amu
(atomic mass unit), also could be written as 60.5 or 500 mmu
(milli mass units). Peptides were filtered by a Ranked Preliminary
Score of 1 and probability of 16e
23. We were able to retain high
quality single scan unique peptide identifications. The peptides
were independently identified; a distinct or representative protein
is assigned to each peptide. The reason was to avoid ‘‘double-
counting’’ when quantifying. We only grouped proteins for
quantification. Homologous region peptides were quantified with
the first protein in the database (alpha-numerically). For example,
aortic actin (swissprot code ACTA) contains a peptide, QEY-
DESGPSIVHR, also found in cytoplasmic actin (ACTB) but was
only quantified in ACTA. Results were filtered to less than 5%
False Discovery Rate (FDR), defined by number of proteins
identified with reversed sequences divided by the total number
proteins identified minus reversed number, multiplied by 100.
Immunoprecipitation (IP) and Western Blot Analysis
IP and western blot analyses were performed as previously
reported [8]. Briefly, 1 mg protein lysates were pre-cleared with
protein A resin followed by incubation with 10 mg of antibody
overnight. The second day the lysates were incubated with protein
A resin for 2 hr, then the precipitated proteins were washed and
boiled in protein loading buffer. 10 ml of the pull-down sample or
30 mg of total protein lysates were separated by SDS/PAGE. After
transferred to the nitrocellulose membrane, the membrane was
incubated with primary and secondary antibodies, the bands of
identity were visualized with HyGlo Quick Spray (Denville
Scientific Inc. Metuchen, NJ).
Mitochondria Isolation
Intact mitochondria was isolated from rat liver using a protocol
as previously described [24]. Briefly, the perfused rat liver was
minced and homogenized in IBc buffer (0.01 M Tris-MOPS,
0.01 M EGTA/Tris, 0.2 M sucrose, pH 7.4) with protease
inhibitor cocktail (Sigma). The homogenate was then centrifuged
at 600 g for 10 min twice at 4uC. The supernatant was transferred
and centrifuged at 7,000 g for 10 min. The supernatant part was
collected as the cytosol; and the pellet was washed twice and saved
as mitochondria.
BH4 Assay
BH4 was quantified on a HPLC with an electrochemical
detector as previously reported [19]. Liver tissue or cells were lysed
Figure 1. Purification of GCH1 and its interacting proteins. (A) Flow chart showing the procedure for purification and characterization of
GCH1 complexes from rat organ (brain, heart, liver and kidney). (B) Protein samples from different steps of protein purification by IgG and GCH1 from
rat liver were separated by SDS-PAGE, (B) stained with Gelcode Blue and (C) analyzed by Western blot analysis against GCH1 antibody. IgG and GCH1
purified samples from rat heart were (D) silver stained and (E) analyzed by Western blot analysis against GCH1. MK, molecular weight marker; Ig, IgG;
GCH, GCH1; FL, flow-through; FLG, Flag tag, Flg-GCH is cell lysates from FLAG-GCH1 over-expressing HEK cells, used as positive control.
doi:10.1371/journal.pone.0033991.g001
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10 min, 4uC). The supernatants were filtered through a 10 kDa
cutoff Amicon Ultra Centrifugal Filters (Millipore, Ireland) and the
flow-through was analyzed for BH4 concentration by HPLC. The
BH4 levels were normalized to protein concentrations.
Data Analysis
The searched proteins were filtered using the following criteria
to ensure high quality of data: 1) a high spectral count (MS/MS
spectra identified as peptides for a protein) for unique proteins in
the GCH1 protein complexes or the proteins detected at least
twice more than the proteins in IgG complexes); 2) The proteins
appeared in at least two out of five independent experiments
(eliminated proteins that appeared in less than two indepen-
dent experiments); and 3) some IgG proteins were removed.
UniProtKB/Swiss-Prot and PubMed were used for gene ontology
(GO) annotations.
Data are expressed mean6standard deviation (SD). Compar-
isons between 2 groups were by 2-way ANOVA, followed by post-
hoc test with Duncan’s Multiple Range test. A value of P,0.05
was considered statistically significant.
Results
Purification of GCH1 protein complexes
As shown in Figure S1-A, there were no stained proteins in
lane 2 (Eluate 3) indicating that all the unbound GCH1
antibodies were completely eluted from the agarose after
crosslinking and elution. After incubation with immobilized
GCH1 antibody, there was no detectable GCH1 in the flow-
through from both GCH1-HEK cell lysates and liver samples by
western blot analysis (Lane 3, 4 of Figure S1-B) while there was
large amount of GCH1 pulled down in the Elution 1 (Lane 5 and
Lane 6). These results indicate that the immobilized GCH1
antibody was very effective in pulling down endogenous GCH1
from cells and animal tissues.
To reduce the potential contaminations of plasma proteins, we
perfused the whole rat through left ventricle by PBS for 15 min.
The tissue homogenate were precleared with a combination of
protein A/G plus agarose and agarose conjugated IgG for 2 hr to
minimize the non-specific binding to the agarose beads and the
antibody. Figure 1A outlined the purification procedure. The
conjugated rabbit IgG was used as a control. As there is high
expression level of GCH1 in the liver, we verified the purification
by running the purified samples in SDS-PAGE gel followed with
coomassie staining (Figure 1B). For the purified GCH1 complexes
from heart (Figure 1D), brain and kidney (data not shown in
Figures), the samples were run on a SDS-PAGE followed with
silver staining. As shown in Figure 1 C (liver samples) and
Figure 1E (heart samples), the GCH1 protein (,27 kDa) was able
to be visualized by western blot analysis and there were strong
GCH1 bands in the GCH1 antibody but not IgG pull-down
complexes. The Flag-GCH1 cell lysates were used as a positive
control for GCH1 as these cells are over-expressing GCH1 as we
described previously [19,23]. Compared to the IgG pull down
samples, there were extra bands in GCH1 pull down eluates
visualized by the staining (Figure 1B and Figure 1D), indicating
that they are possible GCH1-interacting proteins.
Identification of GCH1 interacting proteins in rat liver
By LC/MS, we identified 564 unique peptides and 158 proteins
in IgG pull-down complexes with FDR at 1.1% and 3.8%
respectively. However, in the GCH1 complexes, 865 unique
peptides and 289 proteins were detected with FDR of 1.6% and
4.8% (Data not shown). After filtering out the proteins that bind to
IgG or have total scan count less than 2, we identified 18 unique
proteins in GCH1 pull down complexes from rat liver (Table 1,
Table S1). Among the 18 proteins, GCH1 was identified in all five
Table 1. Identified Proteins in GCH1 pull-down rat liver samples.
Uniprot Gene name Biological Process
P22288 GCH1 BH4 biosynthesis
B0BNA7 Eukaryotic translation initiation factor 3 subunit I Protein biosynthesis
P70552 GCH1 feedback regulatory protein Negative regulation of GCH-1 activity
P85108 Tubulin beta-2A chain microtubule-based movement, protein polymerization
P62832 60S ribosomal protein L23 translation
P47819 Glial fibrillary acidic protein response to wounding
P39052 Dynamin-2 receptor-mediated endocytosis
Q4KLZ6 ATP-dependent dihydroxyacetone kinase glycerol metabolic process
Q5RK09 Eukaryotic translation initiation factor 3 subunit G Protein biosynthesis
P04905 Glutathione S-transferase Mu 1 Conjugation of reduced glutathione to hydrophobic electrophiles
Q4G061 Eukaryotic translation initiation factor 3 subunit B Protein biosynthesis
P45953 Very long-chain specific acyl-CoA dehydrogenase Fatty acid metabolism, Lipid metabolism
P04904 Glutathione S-transferase alpha-3 Conjugation of reduced glutathione to hydrophobic electrophiles
P30839 Fatty aldehyde dehydrogenase formaldehyde metabolic process, oxidation-reduction process,
response to reactive oxygen species
P63036 DnaJ homolog subfamily A member 1 DNA damage response, detection of DNA damage
P16970 ATP-binding cassette sub-family D member 3 peroxisomal long-chain fatty acid import
Q6IFW5 Keratin, type I cytoskeletal 1 maintenance of corneal epithelium integrity
Q6IFV3 Keratin, type I cytoskeletal 15 intermediate filament-based process
doi:10.1371/journal.pone.0033991.t001
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Using gene ontology classification, most of the identified proteins
were found related to the biological process of metabolism (38%)
and protein biosynthesis (28%) (Figure 2A, Table S2). About 28%
of the GCH1 interacting proteins have the molecular function of
enzyme activities such as GTPase, ATPase, transferase and
dehydrogenase activities; and many of these proteins bind GTP,
ATP, nucleotide or metal ions (Figure 2B). Further, the GCH1-
interacting proteins were diversely distributed in cytoplasm (36%),
nucleus (24%), and membrane (24%) as well as mitochondria,
ribosome and peroxisome (Figure 2C and Table S2). Figure S2
shows representative tandem mass spectra of tryptic peptide
(DPSQIDSNEPYMK) of EIF3I, one of the identified GCH1
protein partners.
We further validated six identified proteins partners of GCH1:
GFRP, EIF3I, DNJA1, ALDH, TBB2A and VLCAD by western
blot analysis of pull-down complexes (Figure 3). Liver protein
straight lysates were used as positive controls. All six proteins were
clearly detected in GCH1 pull-down samples but not IgG pull-
down samples, indicating that these proteins interact specifically
with GCH1 in vivo. We also performed reverse IP using antibodies
against these 6 proteins; unfortunately, these antibodies did not
work well for IP with rat samples (Data not shown).
The interaction of GCH1 and GFRP in different tissues
To examine whether the identified proteins in liver also
interacts with GCH1 in other organs, we purified GCH1
complexes from brain, heart and kidney. IgG was used as a
control. As shown in Figure 4A, GCH1 was purified from these
organs by GCH1 agarose but not IgG agarose. Besides the 27 kDa
band (very weak in the kidney samples), the predicted molecular
weight of GCH1, there was a strong band around 20 kDa detected
by western blot using GCH1 antibody in brain, heart and kidney
samples, which we suspect might be a different isoform of GCH1.
Interestingly, we found high levels of GFRP in the GCH1 pull-
down complexes from liver samples but not from brain, heart and
kidney samples (Figure 4B), although there was a high GFRP
expression in kidney (Figure 4C). As GFRP is the only well-
established protein that interacts with GCH1, we tested GCH1-
GFRP interaction in HEK cells. When we immunoprecipitated
GCH1 from the GCH1 over-expressing stable HEK cell line
established by our lab [19,23], we were unable to find GFRP in
pull-down samples as well as the whole cell lysates (Figure 4D).
This might be due to low expression level of GFRP in HEK cells.
Liver tissue homogenate was used as a positive control for GCH1
and GFRP. Thus we further over-expressed HA-GFRP in FLAG-
GCH1-HEK cells (see method). Interestingly the pull-down assay
with either Flag or HA tag indeed showed the interaction between
GCH1 and GFRP (Figure 4E, 4F). As the function of GFRP in
regulating GCH1 activity was still controversial, we further
examined whether GFRP expression affects BH4 biosynthesis.
However, in the HEK cells stably expressing GCH1, we did not
detect any difference in BH4 production with pcDNA or GFRP
transfection (Figure S3). These results indicate that GFRP might
not be the major regulator of GCH1 in vivo or its impact on GCH1
activity or BH4 production is tissue specific.
Figure 3. The interactions of GCH1 with its 6 protein partners
identified by ESI/LC/MS were validated in rat liver by western
blot analysis. The purified GCH1 complexes from rat liver were
separated by SDS-PAGE and then immunoblotted with different
antibodies as indicated. The blots were representatives of five
independent biological repeats.
doi:10.1371/journal.pone.0033991.g003
Figure 2. Gene ontology analysis of identified GCH1-interact-
ing proteins in liver. The identified GCH1-interacting proteins were
characterized according to their involvement in biological process (A),
molecular functions (B) and cellular localization (C).
doi:10.1371/journal.pone.0033991.g002
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TBB2A and VLCAD
Interestingly, one of the identified GCH1 protein partners in the
rat liver, EIF3I, is highly expressed in all the organs we tested (liver,
brain, heart, and kidney, Figure 5A). The interaction of EIF3I and
GCH1 was verified by western blot analysis in all the GCH1
complexes purified from brain, heart and kidney as shown in
Figure 5B. Except ALDH and VLCAD had lower expression in the
brain, all other proteins are abundantly expressed in the four tested
organs (Figure 5A). However, DNJA1 and ALDH only showed
interaction with GCH1 in heart and kidney; TB22A bound GCH1
only in the brain; and no interaction was observed for VLCAD with
GCH1 in brain, heart and kidney. These results indicate that EIF3
might be a general (ubiquitous?) interactor of GCH1 in all organs.
The distribution of GCH1 in the mitochondria
It was surprising to find that GCH1 interacts with VLCAD, a
mitochondrial protein. The question is whether GCH1 had any
distribution in the mitochondria? The mitochondrion from liver,
heart and kidney were then prepared. COX-1 was used as a marker
for mitochondria. As 90-kDa heat shock protein (HSP90) is mainly
in the cytoplasm, thus it was used as a cytosolic marker. As shown in
Figure 6A, GCH1 expressed highly in the liver mitochondrial
fraction while it was almost undetectable in the mitochondrion from
heart and kidney probably due to its low expression in these tissues
(Figure 6A). However, there was an obvious band around 37 kDain
the mitochondrial portion of heart and kidney, which might be an
unidentified GCH1 isoform. To further confirm the existence of
GCH1 in the mitochondria, we pulled down GCH1 from liver
mitochondrial extraction using conjugated IgG and GCH1
antibody and detected abundant GCH1 in the liver GCH1 pull-
down mitochondria (Figure 6B). Additionally, we also found
mitochondrial distribution of GCH1 in GCH1 HEK cells [19,23]
and hearts of GCH1 transgenic mouse (data not shown here).
Furthermore, to examine the function of GCH1 in the mitochon-
dria, we used our established methods to determine mitochondrial
BH4 and we were able to detect fair amount of BH4
(3.3261.36 pmol/mg protein) in the liver mitochondria, about 1/
10th of total BH4 levels in the liver (Figure 6C).
Discussion
The results of this study reveal several novel findings related to
GCH1 regulation and function. First, we have identified 17 unique
Figure 4. The interaction of GCH1 with GFRP in different organs. GCH1 and its interacting proteins were purified from brain, heart, liver and
kidney, and analyzed by western blot against GCH1 antibody (A) and GFRP antibody (B). EL1 is the first eluate, EL2 is the second eluate. Eluates from
IgG conjugated column were used as controls. Protein lysates from different organs were immunoblotted with GFRP antibody and HSP90. HSP90 was
used as a loading control (C). HEK cells stably over-expressing GCH1 (GCH1-HEK) were immunoprecipitated with IgG or GCH1 antibody and
immunoblotted against GFRP and GCH1. Straight cell lysate of GCH1-HEK cells (Lysate) was also loaded for comparison (the first lane). Liver
homogenate was used as a positive control (D). HEK cells were transiently transfected with Flag-GCH1, HA-GFRP or pcDNA, and immunoprecipitated
with Flag tag (E) or HA tag and immunoblotted with GCH1 and GFRP antibodies. In (E), cell lysates (the first lane) from HEK cells transfected with
FLAG-GCH1 and HA-GFRP were used as positive controls for GFRP and GCH1 expression.
doi:10.1371/journal.pone.0033991.g004
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Second, we have demonstrated that many GCH1 interactors
interact with GCH1 in an organ specific manner. GCH1 interacts
with GFRP and VLCAD in the liver, with TB22A in the liver and
brain, with DNJA1 and ALDH in the liver, heart and kidney and
with EIF3I in all four organs. Third, GCH1 interacts with
mitochondrial proteins and itself has distribution in mitochondria.
These results indicate that GCH1 might have broader functions
beyond BH4 biosynthesis and the regulation of GCH1 by its
interactors might be different in different organs.
It is already known that GCH1 has a number of protein
partners. GCH1 interacts with GFRP in rat liver [13,14],
rabphilin-3A in PC12 cells [25], tyrosine hydroxylase in
drosophila [21] and activator of HSP90 in the human brain
library [20]. In our previous study, in HEK293 cell lines, we found
twenty-nine proteins interacted with GCH1 when GCH1 is over-
expressed in these cells [19]. However, except GFRP, none of the
reported protein partners were isolated in endogenous GCH1
protein complexes from native mammalian organs. This is likely
due to GCH1 has unique protein partners in different organs or
cells. However, it is also possible that the exogenous over-
expression may result in non-physiological interactions among
proteins. To determine protein-protein interactions, pull-down
assay of the endogenously expressed protein is desirable but it is
also very challenging due to low abundance of the target proteins
and the requirement of high-affinity antibodies. In this study,
GFRP was identified consistently in liver GCH1 complexes but
not IgG complexes (Table S1) indicating that our methodology
works well in identifying the interacting proteins. Interestingly,
GCH1 precipitated with GFRP in liver but not in kidney which
also contains high GFRP levels (Figure 4B and 4C). Similarly, we
have validated that except EIF3I, four other GCH1 partners
identified in liver have organ-dependent interactions in other
organs tested. There are several possible reasons leading to this
differential protein-protein interaction. First, the post-translational
modification status of GCH1 or its partners might be different in
different organs. We and others have reported that GCH1 can be
phosphorylated [23,26] and ubiquitinated [27]. Phosphorylation
or ubiquitination allosterically regulates proteins to associate or
dissociate with other proteins. In endothelial cells, laminar shear
stress causes dissociation of GCH1 and GFRP probably by
increasing GCH1 phosphorylation [16]. Second, rat GCH1 might
have different isoforms in different organs. Protein isoforms may
Figure 5. The interaction of rat liver GCH1-interacting proteins
with GCH1 in brain, heart and kidney determined by western
blot analysis. (A) The protein lysates from different rat organs were
immunoblotted with antibodies indicated. (B) The GCH1 protein
complexes purified from different organs were immunoblotted with
the indicated antibodies.
doi:10.1371/journal.pone.0033991.g005
Figure 6. The distribution of GCH1 in mitochondria. Cytosolic
and mitochondrial fractions were extracted from liver, heart and kidney
and probed for GCH1, COX-1 and HSP90 by western blot analysis (A).
The liver mitochondrial fraction was immunoprecipitated with IgG or
GCH1 and immunoblotted with GCH1 antibody. IP, Immunoprecipita-
tion, IB, western blot analysis (B). BH4 levels from liver and liver
mitochondria were assayed by HPLC and normalized by protein
concentrations (C) (N=4). *P,0.05 vs. Liver BH4.
doi:10.1371/journal.pone.0033991.g006
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variability. There are at least three GCH1 isoforms identified in
human liver [28] and one isoform in human monocytes [29], but
up to now there is only one rat GCH1 isoform that has been
reported [30]. We speculate that there might be other GCH1
splicing variants in rat as there are extra bands detected by GCH1
antibodies (Figure 1C, 4A and 6A). Also, as a 71 kDa protein,
VLCAD showed a strong band at about 55 kDa in the brain but
not in other tissues (Figure 5A). Third, the abundance of GCH1 or
its partners might vary in different organs. The liver has the
highest and the kidney has the lowest GCH1 expression level
(Figure 4A). However, both the liver and kidney have comparable
amount of GFRP but the endogenous GFRP is undetectable by
western blot in brain, heart and HEK cell lines (Figure 4C and 4F).
It is proposed that two molecules of a pentameric GFRP are
associated physically with one molecule of a decameric GCH1
[14]. The mismatched GCH1 and GFRP expression might result
in their distinct interaction profiles in different organs. Similarly, in
the brain, ALDH has very low expression while TBB2A has much
higher expression (Figure 5A). This different protein abundance
might contribute to their different interactions with GCH1 in the
brain.
Noticeably, EIF3I interacts with GCH1 in all four rat organs.
EIF3I is a subunit of EIF3 complex which organizes a web of
interactions among several EIFs required in the initiation of
protein synthesis [31]. Interestingly, we have also found that other
components of EIFs, EIF3G and 60S ribosomal protein L23
associate with GCH1 in the liver. Moreover, in the yeast, GCH1 is
identified in the affinity purified EIF3 complexes [32]. Further
studies are warranted to determine whether GCH1 participates in
the regulation of translation. However, EIF3I is also an important
modulator of cell signaling. EIF3I is originally identified to
associate with and be phosphorylated by type II TGF-b receptor,
and thus named as TGF-b receptor-interacting protein-1 (TRIP-1)
[33]. EIF3I modulates the TGF-b1-stimulated wound repair [34]
and gene expression response [35]. Intriguingly, over-expression of
GCH1 accelerates refractory wound healing in diabetic mice [36].
As GFRP has low expression in several organs and does not
interact with GCH1 in the kidney, the observation that EIF3I
associates with GCH1 in all organs we tested indicates that EIF3I
might work as a general regulator of GCH1 which remains to be
determined.
Accumulating evidence has indicated that GCH1 might be an
important regulator of mitochondrial function. The GCH1
inhibitor triggers mitochondrial depolarization in neurons [37]
and mitochondrial swelling in heart [38]. Overexpression of
GCH1 in the heart rescued the dysfunctional mitochondrial
permeability transition pore induced by high glucose [39]. To our
knowledge, our study is the first report demonstrating that GCH1
distributes in the mitochondria and interacts with fatty acid
metabolism enzyme VLCAD. However, we did not find
mitochondrial targeting sequence in GCH1. Thus GCH1 might
translocate from cytosol into mitochondria like some nitric oxide
synthase (NOS) isoforms with unclear mechanisms [40]. As BH4 is
an essential cofactor for NOS isoforms, it will be noteworthy to
study the regulation and function of GCH1 in relating to
mitochondrial NOS. Furthermore, VLCAD has been identified
to play a critical role in catabolism of long-chain fatty acids
activity. The dysregulation of VLCAD is associated with
production of oxidative stress and reactive oxygen species [41].
The association of VLCAD with GCH1 in mitochondria suggests
that GCH1 might regulate fatty acid metabolism and exerts its
protective effect to reduce oxidative stress originated from
mitochondria.
The findings of this study have important implications to our
understanding of GCH1 function and regulation. The identifica-
tion of endogenous GCH1 differentially interacts with its partners
indicates that the regulation of GCH1 is very complicated and
organ-dependent. GCH1 might involve in the protein translation,
fatty acid metabolism and mitochondrial function which might
provide new mechanisms for its beneficial effects in cardiovascular
and neurological diseases. As EIF3I has an intensive interaction
with GCH1 in all organs, it might be an important and general
regulator of GCH1 function.
Supporting Information
Figure S1 The conjugation of GCH1 antibody with
agarose. GCH1 antibody was crosslinked by using Pierce
Crosslinking Kit. The resin was then washed and eluted to
remove the non-crosslinked antibody. The first and third eluates
(in Figure 1A, Lane 1 and 2), as well as and the flow-throughs and
eluates from the conjugated antibody incubated with GCH1-HEK
stable cell lines or liver samples were collected (Figure 1A and 1B,
Lane 3, 4, 5, 6) and verified by Coomassie staining (Figure 1A) and
by western blot analysis (Figure 1B) with GCH1 antibody (primary
antibody).
(TIF)
Figure S2 ESI/LC/MS analysis of the tryptic peptides
of rat liver samples identified one of the GCH1 protein
partners-EIF3I. Representative tandem mass spectra of tryptic
peptide (DPSQIDSNEPYMK) of EIF3I. Bond cleavages were
indicated in the peptide sequence resulting in b/y ions.
(TIF)
Figure S3 GFRP over-expression did not alter BH4
production in GCH1-overexpressing HEK cells. In the
HEK-GCH1 stable cell lines, pcDNA and GFRP (4 mg each) were
transfected into the cells and GCH1 was induced by tetracycline
for 24 hours. BH4 concentration was determined and expressed as
pmol/mg protein. NS, no significant difference between the two
groups (N=3).
(TIF)
Table S1 The spectra counts of five independent
repeats from GCH1 or IgG pull-down complexes. Ex-
Experiment.
(DOCX)
Table S2 The result of GO analysis of the identified
GCH1 protein partners.
(DOCX)
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